Sunovion, PsychoGenics Nondopamine Schizophrenia Drug Meets Phase 2 Endpoint

Sunovion Pharmaceuticals (Sunovion) and PsychoGenics recently announced positive phase 2 results for a new schizophrenia treatment, SEP-363856. The two organizations believe that the treatment causes a regulation in dopamine, norepinephrine, and serotonin transmission, as well as effects the brain’s immune system—effects that are believed to mediate the effects of other current antipsychotic drugs.

According to statements from Sunovion leadership, the two organizations plan to advance the development of SEP-363856 as quickly as they are able to. PsychoGenics seeks to provide the best validated disease models and comprehensive pre-clinical capabilities to help companies discover the next . . .